AbbVie Raises Full-Year Revenue Guidance Following Strong Immunology and Neuroscience Performance
AbbVie (ABBV) raised its full-year revenue guidance to $67.8 billion during its Q3 2026 earnings call, driven by robust sales in its immunology and neuroscience portfolios. The company is successfully transitioning away from patent-expiry headwinds associated with Humira by expanding the market share of newer therapies like Skyrizi, which now captures half of all new patient starts for inflammatory bowel disease. In addition to immunology growth, AbbVie's neuroscience division is seeing significant momentum following the approval of Juvmo for Parkinson's disease. Management expects its Parkinson's franchise to reach peak sales exceeding $5 billion by 2028. Financially, the company remains strong with $14 billion in free cash flow generated over the first nine months of the year, supporting a recent 5.2% dividend increase and long-term deleveraging goals.
Tickers: $ABBV
Topics: dividend growth drug approval earnings report free cash flow revenue guidance
Read the full article at Motley Fool
Part of the story AbbVie Raises Full-Year Revenue Guidance Following Strong Immunology and Neuroscience Performance (4 articles)